Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 28, 2025
Product Development
Rare Disease Spotlight: A genetic seizure disorder with a growing market, pipeline
As the first Dravet syndrome products establish the market, the pipeline moves toward selective small molecules and genetic therapies
BioCentury | Oct 14, 2024
Deals
Lundbeck bolts on Longboard, gains anticonvulsive in $2.6B deal
Danish pharma eyeing growth beyond loss of exclusivity for Rexulti, aiming for broad label in rare epilepsies
BioCentury | Apr 16, 2024
Product Development
Clinical report: Proof of concept for Allay’s implantable analgesic, with Singapore tech
Plus: Intra-Cellular’s Caplyta scores a win in major depressive disorder; and readouts for Marinus, Ultragenyx weigh on shares
BioCentury | Mar 12, 2024
Product Development
Clinical report: takeaways from Amylyx’s ALS journey
Plus: A comeback for Regulus? And updates from Acadia, MoonLake, Ventyx, Acelyrin, Sanofi and more
BioCentury | Feb 28, 2024
Regulation
Minerva setback doesn’t preclude big year for schizophrenia
With Karuna’s PDUFA date and several readouts on the way, 2024 is still looking like an important year for progress in treating the disease
BioCentury | Feb 8, 2024
Product Development
Bristol Myers’ growing challenge
The clinical and commercial successes needed for Bristol Myers to navigate its upcoming patent cliff
BioCentury | Feb 1, 2024
Data Byte
World’s first TIL therapy among FDA’s five February PDUFA dates
An approval for Iovance’s lifileucel would mark the entry of immune cell therapies into solid tumors
BioCentury | Jan 24, 2024
Data Byte
Schizophrenia pipeline: two PDUFA dates and a dozen readouts in 2024
A look ahead to the schizophrenia milestones coming this year, and the mechanisms behind them
BioCentury | Jan 20, 2024
Finance
Buysiders are all about market-creating catalysts in 2024
BioCentury’s 32nd Buyside View finds MASH, obesity and pain are among the year’s most closely-watched categories
Items per page:
1 - 10 of 549